DEA extends telehealth prescription waivers, puts proposed rules on hold

Why This Topic Matters

The update affects telehealth-based prescribing workflows, continuation of care for established patients, and planning around federal telemedicine policy changes. It is especially important for practices managing controlled-substance prescribing, behavioral health care, and substance use disorder treatment under evolving DEA guidance.

Article Sections

1. Telehealth

   Introduces the policy update and the general scope of the DEA’s temporary telemedicine extension. It frames the article around federal telehealth prescribing policy and the timing of the extension.

2. Telehealth is the rule, audio-only the exception

   Summarizes the communication modalities discussed in the temporary rule and the circumstances under which telehealth visits may proceed differently. It focuses on the general telemedicine framework described by the agency.

3. Stakeholders give a thumbs up

   Highlights reactions from professional associations and telehealth-focused organizations. It emphasizes stakeholder perspectives on access, continuity of care, and treatment availability.

4. Watch for more proposed rules

   Covers the DEA’s next steps in the rulemaking process and the expected review of public comments. It also addresses the broader timeline for additional regulatory action.